Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10339554 | 0.79 | HSD11B1 (0.48) | HSD11B1HSD11B2CYSLTR2CYSLTR1EGFR | |
| SCHEMBL31326461 | 0.79 | HSD11B1 (0.48) | HSD11B1HSD11B2CYSLTR2CYSLTR1EGFR | |
| SCHEMBL6704988 | 0.79 | ALDH1A1 (0.41) | HSD11B1GRM2HTR2AKMT2AGRM6 | |
| SCHEMBL6704991 | 0.79 | ALDH1A1 (0.41) | HSD11B1GRM2HTR2AKMT2AGRM6 | |
| SCHEMBL7730728 | 0.79 | ALDH1A1 (0.41) | HSD11B1GRM2HTR2AKMT2AGRM6 | |
| SCHEMBL6751381 | 0.79 | ALDH1A1 (0.41) | HSD11B1GRM2HTR2AKMT2AGRM6 | |
| SCHEMBL12884709 | 0.76 | HSD11B1 (0.57) | HSD11B1HSD11B2CYSLTR2CYSLTR1EGFR | |
| SCHEMBL4235542 | 0.74 | HSD11B1 (0.55) | HSD11B1HSD11B2CYSLTR2CYSLTR1EGFR | |
| SCHEMBL1222515 | 0.74 | HSD11B1 (0.55) | HSD11B1HSD11B2CYSLTR2CYSLTR1EGFR | |
| SCHEMBL30671677 | 0.72 | SMN1; SMN2 (0.42) | HSD11B1HSD11B2CYSLTR2CYSLTR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152670-A1 | Novel aminoindanes | CURRY KENNETH (CA) | 2004-08-05 | — | — | US | disclosed |
| US-6699909-B1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS | PRESCIENT NEUROPHARMA INC. (CA) | 2004-03-02 | — | — | US | disclosed |
| US-6699909-B1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS | PRESCIENT NEUROPHARMA INC. (CA) | 2004-03-02 | — | — | US | disclosed |
| US-6699909-B1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS | PRESCIENT NEUROPHARMA INC. (CA) | 2004-03-02 | — | — | US | disclosed |
| EP-1194399-A2 | NOVEL AMINOINDANES | Prescient Neuropharma Inc. (CA) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001002340-A2 | NOVEL AMINOINDANES | IGT PHARMA INC. (CA) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152670-A1 | Novel aminoindanes | GRM1, GRM2, GRIN1 | HSD11B1 1956/4885HSD11B2 2470/4885GRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.